Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $26.34 USD
Change Today -1.07 / -3.90%
Volume 696.9K
MDCO On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

medicines company (MDCO) Snapshot

Open
$27.52
Previous Close
$27.41
Day High
$27.81
Day Low
$26.30
52 Week High
03/20/15 - $32.44
52 Week Low
10/14/14 - $19.92
Market Cap
1.7B
Average Volume 10 Days
959.5K
EPS TTM
$-0.59
Shares Outstanding
66.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICINES COMPANY (MDCO)

medicines company (MDCO) Related Businessweek News

No Related Businessweek News Found

medicines company (MDCO) Details

The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for use in patients undergoing percutaneous coronary intervention; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; Minocin IV, an antibiotic for the treatment of infections due to gram-negative bacteria; Orbactiv for the treatment of acute bacterial skin and skin structure infections; PreveLeak, a mechanical vascular and surgical sealant; ready-to-use formulation of Argatroban for the treatment of thrombosis; and Recothrom, a human recombinant thrombin used as an aid to hemostasis, as well as acute care generic products for acute cardiovascular, surgery and perioperative care, and serious infectious diseases. Its development stage products include Cangrelor for the prevention of platelet activation and aggregation; IONSYS for the short-term management of acute postoperative pain; Raplixa, a dry powder topical formulation of fibrogen and thrombin; and RPX-602 for the treatment of bacterial infections. The company’s products under development also comprise ABP-700, an intravenous anesthetic agent for moderate or deep sedation and general anesthesia in patients undergoing diagnostic or therapeutic procedures; LN-PCSsc for the treatment of hypercholesterolemia; Carbavance, an antibiotic agent for the treatment of hospitalized patients with bacterial infections; and MDCO-216, a novel biologic product to reverse atherosclerotic plaque development and reduce the risk of ischemic events in patients with ACS. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize ALN-PCSsc. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.

727 Employees
Last Reported Date: 03/2/15
Founded in 1996

medicines company (MDCO) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $793.3K
President, Chief Financial Officer, Treasurer...
Total Annual Compensation: $569.3K
Chief Accounting Officer and Senior Vice Pres...
Total Annual Compensation: $398.2K
Compensation as of Fiscal Year 2013.

medicines company (MDCO) Key Developments

The Medicines Company Announces U.S. Food and Drug Administration Approves New Formulation of Minocin (Minocycline) for Injection

The Medicines Company announced that the U.S. Food and Drug Administration has approved a supplemental new drug application (sNDA) for a new formulation of MINOCIN (minocycline) for Injection. The FDA has also granted Qualified Infectious Disease Product (QIDP) designation for the new formulation of MINOCIN for Injection under the Generating Antibiotic Incentives Now Act (GAIN Act). The designation, the third granted to a product in the company’s infectious disease portfolio, would qualify MINOCIN for Injection for priority review and five years of marketing exclusivity upon an approval of the additional potential indications. Multi-drug resistant Acinetobacter is considered to be a serious antimicrobial resistance threat by the US Centers for Disease Control and Prevention (CDC). CDC estimates the number of deaths with onset in hospitalized patients due to multi-drug resistant Acinetobacter to be higher than those attributed to multi-drug resistant Pseudomonas aeruginosa. According to published estimates (Spellberg and Rex, Nature Reviews/Drug Discovery, 2013), there may be up to 80,000 infections due to Acinetobacter species annually in the US, and one million deaths worldwide. MINOCIN for Injection is a tetracycline derivative approved in the U.S. The approved indications for MINOCIN for Injection includes the treatment of infections due to susceptible strains of several important designated gram-positive and gram-negative pathogens, including infections due to Acinetobacter species, which typically occur in hospitalized patients.

The Medicines Company to Receive Marketing Approval for its Cardiovascular Drug Cangrelor

The Medicines Company is one step closer to receiving marketing approval for its cardiovascular drug cangrelor in the United States as it reported a decline in revenues for Angiomax. The US FDA's staff recommend the approval of US firm The Medicines Company's Kengreal (cangrelor) under a narrowed indication, according to briefing documents released ahead of a meeting by the FDA's Cardiovascular and Renal Drugs Advisory Committee. The US firm is seeking approval for cangrelor as an adjunct treatment to percutaneous coronary intervention (PCI) in order to reduce the risk of periprocedural ischaemic complications, including myocardial infarction and stent thrombosis in patients for whom oral purinergic receptor P2Y G protein-coupled 12 (P2Y12) inhibitor treatment is contraindicated, and for whom glycoprotein IIb/IIIa receptor antagonists are unlikely to be used. This is the second submission to the FDA for cangrelor, and the firm has included sensitivity analysis requested by the agency that removed disputed endpoints from the PHOENIX trial and demonstrated the drug's efficacy with greater certainty.

The Medicines Company Provides Earnings Guidance for the First Quarter of 2015

The Medicines Company provided earnings guidance for the first quarter of 2015. For the quarter, the company expects net revenue in the range of $125 million to $130 million, which reflects a 29% to 26% decrease from the $177.2 million in net revenue reported for the first quarter of 2014. The decrease in net revenue is a result of lower worldwide net revenue from sales of Angiomax (bivalirudin)/Angiox (bivalirudin), which the company expects to be in the range of $97 million to $105 million compared to $155.7 million in the first quarter of 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MDCO:US $26.34 USD -1.07

MDCO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BTG PLC 755.50 GBp -3.00
Impax Laboratories Inc $46.66 USD -2.89
Integra LifeSciences Holdings Corp $60.75 USD -0.56
Krka dd Novo mesto €68.00 EUR -0.01
Skyepharma PLC 321.00 GBp +0.50
View Industry Companies
 

Industry Analysis

MDCO

Industry Average

Valuation MDCO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.5x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICINES COMPANY, please visit www.themedicinescompany.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.